Emergent Biosolutions
As of the edition of 20 October 2026, Emergent Biosolutions runs 11 drugs, 6 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Went quiet | 3 |
| Stopped | 1 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Naloxone | none listed | 10 |
| Rabies vaccine | Ended 2009 (computed from the first US licence) | 0 |
| Brincidofovir | Ends 2034 (patent) | 0 |
| Ansuvimab | Ends 2032 (computed from the first US licence) | 0 |
| Raxibacumab | Ended 2024 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CD4 T-cell surface glycoprotein CD4 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Emergent Biosolutions needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 6 trials led
- Blood and lymph: 1 trials led
- Cancer: 1 trials led